Bone Abstracts

see PP91....

Purpose: In X-linked hypophosphatemia (XLH), elevated serum FGF23 causes low serum phosphorus (Pi) and inappropriately normal 1,25-dihydroxyvitamin D (1,25(OH)2D) levels. We report safety, tolerability and biochemistry markers following single ascending dose administration of KRN23 in adults with XLH.Methods: 38 XLH subjects with baseline FGF23≥30 pg/ml were randomized to receive single doses of KRN23 (K) or placebo (P) either (0.003&#15...

Purpose: In X-linked hypophosphatemia (XLH), elevated serum FGF23 causes low serum phosphorus (Pi) and inappropriately normal 125-dihydroxyvitamin D (125(OH)2D) levels. We report PK and PD of KRN23 following single ascending dose administration in adults with XLH.Methods: 38 XLH patients with baseline FGF23≥30 pg/ml were randomized to receive a single dose of KRN23 (K) or placebo (P) either i.v. (0.003–0.3 mg/kg) or s.c. (0.1–1...

Introduction: Gamma type nails are routinely used for the fixation of intertrochanteric fractures of the proximal femur. QCT at the hip is an advanced method that is increasingly being used to estimate BMD and determine the future fracture risk. Yet, implants cause metal artefacts (MA) in CT images, even at the contralateral side due to the high absorption of metal, which may impair BMD accuracy.Methods: Three human cadavers were scanned first without an...

see PP350....

see PP17....

see PP432....

Objective: Wnt/β-catenin pathway is a main regulator of bone remodeling, but might be inhibited in cartilage in osteoarthritis (OA). We here investigated the effect of mechanical loading in Wnt activation and the expression of Wnt antagonists in the joint tissues.Methods: Topgal mice were used. Mice underwent partial meniscectomy (Mnx) and sacrificed at 4, 6, and 9 weeks. Dissected knees were scanned by microCT and then prepared for cryosectioning t...

Introduction: Loss in bone mineral density may occur soon after initiation of adjuvant therapy for hormone-receptor-positive (HR+), breast cancer (BC) and correlates with changes in hormone levels. Adding zoledronic acid (ZOL) to adjuvant treatment for BC can preserve/improve bone mineral density and delay disease recurrence; however, effects of ZOL on endocrine hormone levels are currently unclear.Methods: Probone II assessed the course of endocrine hor...

Introduction: Bone mineral density (BMD) evaluations have shown that adjuvant chemotherapy or endocrine therapy (ET) for early breast cancer (BC) is associated with accelerated BMD loss and increased fracture risk. In recent studies, zoledronic acid (ZOL) increased BMD in premenopausal and postmenopausal women with BC, and improved disease-free survival in some patient subsets compared with no ZOL. The purpose of the current study was to investigate the effect of adjuvant trea...